% 0期刊文章%约翰Sellner %一个茱莉亚Marschallinger卢卡斯Grassner % %赫尔穆特·诺瓦克马丁兔褐% %一个亚历山大Zerbs %路德维希Aigner %尤金Trinka % T非创伤性脊髓损伤神经重症监护室:光谱,录取的原因和预测死亡率(P3.216) % D J神经病学2016% % P P3.216 X % V % 86% N 16补充目的:描述频谱,使患者的住院和死亡的预测因子的非创伤性脊髓损伤(NTSCI)治疗神经重症监护病房(NICU)。首页背景:创伤性脊髓损伤形成异质群体的疾病,这可能发展到危及生命的条件。方法:我们进行了回顾性观察分析NTSCI病例在三级医疗单位治疗中心在2001年和2013年之间。在3937 NICU NTSCI患者招生93人(2.4 [percnt])。使用多元逻辑回归分析,我们对死亡的预测因子包括人口、承认和gc /削弱了病因,原因(格拉斯哥昏迷评分/简化急性生理学分数)的分数。结果:感染和炎症/免疫原因由50 [percnt] NICU住院的情况下,最常见的原因是迅速进步麻痹性痴呆(49.5 [percnt])和大量的呼吸衰竭(26.9 [percnt])。NICU的死亡率为22.6 (percnt),而神经功能改善放电在36.6 [percnt]。死亡率高出3.4折的病人承认由于呼吸衰竭(44 [percnt])相比,进步麻痹性痴呆(13 [percnt])。呼吸功能不全的原因NICU住院(1.38 - -17.9或4.97;P < 0.01),高初始削弱了分数(或1.04; 1.003-1.08; P=0.04), and the development of acute kidney injury throughout the stay (OR 7.25, 1.9-27.5; P=0.004) were independent risk factors for NICU death. Conclusions: Patients with NTSCI account for a subset of patients admitted to the NICU. Prompt admission of patients with progressing paresis and risk factors for fatality should be taken into account. A better understanding of predisposing conditions and further knowledge of management of critically ill patients with NTSCI is mandatory.Disclosure: Dr. Sellner has received personal compensation for activities with Bayer, Biogen Idec, Merck-Serono, Novartis, Genzyme, and Teva. Dr. Grassner has nothing to disclose. Dr. Marschallinger has nothing to disclose. Dr. Dünser has nothing to disclose. Dr. Novak has nothing to disclose. Dr. Zerbs has nothing to disclose. Dr. Aigner has nothing to disclose. Dr. Trinka has received personal compensation for activities Eisai, Ever Neuropharma, Biogen Idec, Medtronics, Bial, GL Pharma, GlaxoSmithKline, Boehringer, Suniovion, Actavis and UCB.Monday, April 18 2016, 8:30 am-7:00 pm %U